Table 3.

Changes in Anxiety, Depression, and Quality of Life After a 4-Week Drug Administration

Modified intention-to-treat analysis	Mosapride CR (n = 54)	Nortriptyline (n = 50)	P-value
Anxiety	–2.1 ± 4.5	–2.1 ± 2.3	0.622
P-value	0.001	< 0.001
Depression	–1.4 ± 4.7	–1.6 ± 3.3	0.784
P-value	0.030	0.001
Quality of life	17.2 ± 19.2	24.9 ± 22.8	0.023
P-value	< 0.001	< 0.001

CR, controlled-release.

Data are presented as mean ± SD.